AAV Delivery 
LVV Delivery 
Other Viral Vectors 
Nanoparticles 
Our Story
Advanced Therapies Are Only as Strong as the Materials Used to Create Them
As the first company to combine proprietary synthetic DNA manufacturing with advanced therapy development and GMP manufacturing, Artis provides a connected path from starting material to clinical production. Our integrated platform helps genetic medicine developers move faster, reduce complexity, and maintain greater control throughout development.
With operations in the United States and Europe, Artis supports programs spanning cell therapy, gene therapy, mRNA, gene editing, vaccines, and other advanced therapeutic modalities. By bringing synthetic DNA, process development, and GMP manufacturing together under one organization, we help transform promising science into clinical reality.
Our Heritage
Our Founding Mission Has Shaped Everything About How We Operate
Our first facility, located in Watertown, Massachusetts, was originally established as Landmark Bio, co-founded by Harvard University, MIT, and leading Boston research hospitals. It was purpose-built for translational development, the critical and often underserved stage where promising science must become a viable manufacturing process.
That founding mission shaped everything about how we operate: deep scientific collaboration, integrated development and manufacturing, and a focus on the early CMC decisions that determine whether a therapy reaches the clinic on time or stalls.
When Artis BioSolutions acquired Landmark Bio and then later Sygoi Technologies in Bilbao, Spain, we did not change that mission. We extended it, connecting downstream manufacturing excellence with upstream synthetic DNA production to create the integrated platform the industry has needed.
Each milestone reflects our commitment to building the infrastructure that genetic medicine needs to move faster, from the DNA through the clinic.
Our Platform
Artis operates an integrated platform that follows the natural path a therapy takes from genetic concept to the clinic.
Synthetic DNA Manufacturing
Artis produces clinical-grade synthetic DNA using a proprietary enzymatic, cell-free process. This replaces traditional plasmid-based bacterial fermentation with a faster, higher-purity alternative, providing the critical starting material that powers everything downstream.
GMP-ready synthetic DNA from mg to gram scale
Enzymatic manufacturing with reduced lead times and higher purity
Supporting mRNA, CAR-T, gene editing, viral and non-viral gene therapy
Capacity for 25+ concurrent customer projects
Advanced Therapy Development and GMP Manufacturing
Our Watertown facility delivers translational development and clinical-scale GMP manufacturing across the broadest range of advanced therapy modalities:
CAR-T and autologous cell therapies
AAV viral vector manufacturing
iPSC-derived therapeutics
Extracellular vesicle programs
mRNA manufacturing and LNP formulation
Our Team
Our Leadership
Artis BioSolutions is led by a team that has collectively deployed over $250 million in capital across seven GMP facilities, launched 50+ active pharmaceutical ingredients, and scaled technologies from bench to global commercial use. Our leadership spans synthetic DNA technology, advanced therapy manufacturing, process science, business development, and commercial strategy.
Brian draws on 25 years in the life sciences and diagnostics industries, with a history of first-to-market successes. His expertise spans business operations, team and facility development, and next-generation platform expansion. He builds highly flexible teams and capabilities that open new markets, enabling the business to expand and innovate without compromising efficiency.
Mike has led scientific operations and strategy across biotechnology and pharmaceutical companies, grounded in a Ph.D. in bioorganic chemistry. His expertise spans oligonucleotide, protein, peptide, and lipid nanoparticle-based drug products, delivery formulations, and analytical development. He shapes the scientific approaches that set new standards for quality and compliance in genomic medicine.
Dr. Kate E. Broderick is a globally recognized expert in DNA and RNA therapeutics with nearly two decades of experience, including executive roles at Maravai LifeSciences and Inovio Pharmaceuticals. Her experience spans synthetic DNA strategy, therapeutic innovation, and industry leadership, including board service with the Alliance for mRNA Medicines and advisory work for the Gates Foundation. She leads the scientific strategy that turns emerging genomic technologies into scalable medicines.
Peter has held global leadership roles across biotech, pharma, and adjacent sectors. His expertise spans business development, M&A, licensing, and operations, with end-to-end development experience across diverse modalities and therapeutic areas. He drives the growth initiatives and strategic partnerships that scale the business and extend its reach into new markets.
Eric offers nearly 25 years of legal leadership across high-growth and complex life sciences organizations. His expertise spans corporate law, intellectual property, governance, M&A, and litigation, including major transactions in biotech and diagnostics. He pairs deep legal acumen with a lasting commitment to companies advancing healthcare and clinical research.
Pamela brings deep expertise in building scalable financial foundations for high-growth life sciences companies. Her experience spans strategic finance, business planning, capital stewardship, and performance management. She designs the financial architecture that brings clarity and discipline to execution, enabling companies to evolve, scale with confidence, and build enterprise value.
Michael’s career spans more than 25 years of quality leadership, from recombinant proteins to advanced cell and gene therapies. His expertise covers quality assurance, quality control, quality systems, and supplier oversight, supporting programs from early clinical development through commercialization. He builds and scales the quality infrastructures that drive operational excellence, ensure patient safety, and strengthen compliance in highly regulated environments.
Gregg brings more than 20 years of biopharmaceutical industry experience with senior leadership roles at Merck and Amgen. His expertise spans biologics process development, clinical manufacturing, and cell sciences and technology. He applies deep technical and operational insight to help programs move from development to manufacturing with speed, rigor, and confidence.
Our Mission
To Power the Next Generation of Genetic Medicines with Truly Synthetic DNA
Our Values
Quality begins at the DNA
By controlling the foundational input, we set every downstream process up for success.
Integrated Execution
Development, analytics, quality, and GMP manufacturing operate as one coordinated system. No handoffs.
True Partnership
We work as an extension of our partners’ teams, with shared accountability, transparency, and scientific collaboration.
Scientific Rigor
Data, process understanding, and technical depth guide every decision.
Speed with Discipline
Accelerating timelines without compromising quality or regulatory readiness.
Build Forward
We invest in technologies that will power tomorrow’s therapies.
Careers
We Are Building the Team Shaping the Future of Synthetic DNA and Advanced Therapies
If you want your work to directly accelerate genetic medicines from concept to clinic, we want to meet you.
Current Career Openings